glp-1 agonist eli lilly The market is projected to exceed 100B USD by 2030 Eli Lilly, Novo Nordisk Strike

Focusing on scale weight as your marker of progress can miss the mark on improved body composition

With 25% obesity prevalence, 90 million diabetics (projected to reach 150 million by 2050), and a patent cliff beginning in 2026, the country may well be presenting a unique convergence of massive medical need, manufacturing capability, and sector opportunity

Toujeo pricing Toujeo, as a mature insulin product, has relatively established pricing, though insulin costs in the United States remain controversial

This is a timely topic, as a case-control study published in 2023 suggests an increased risk for both medullary and all thyroid cancers in patients with diabetes who were being treated with GLP-1 receptor agonists